ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 314

A Double-Blind, Randomized, Controlled, Four Parallel Arm, Dose-Finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Single Intra-Articular (IA) Injections of Fasitibant in Patients with Symptomatic OA of the Knee

Claudia Gabriele Werner1, Karel Pavelka2, Andrea Nizzardo3, Cristina Rossi3, Simona Scartoni3, Maria Paola Contini3, Serena di Molfetta3, Monica Bertolotti3, Angela Capriati3 and Carlo Alberto Maggi4, 1Clinical Research, A. Menarini Research & Business Service GmbH, Berlin, Germany, 2Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 3Clinical Research Department, Menarini Ricerche S.p.A., Florence, Italy, 4Menarini Ricerche S.p.A., Florence, Italy

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Clinical research, Knee, Osteoarthritis, patient outcomes and randomized trials

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Osteoarthritis - Clinical Aspects Poster I: Treatments and Metabolic Risk Factors

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Fasitibant (FAS) is a competitive, potent and selective antagonist of the bradykinin B2 receptor administered IA for SOAK. In response to positive outcomes in a previous exploratory RCT, a phase 2 double blind RCT to evaluate FAS, given as single IA injection at three different doses versus placebo, was conducted at 25 clinical sites in Europe and US.

Methods:

Patients with moderate to severe symptomatic knee OA were randomized (1:1:1:1) to single IA injections of either FAS (1 mg, 2.5 mg or 5 mg) or Placebo (saline) given as 1 ml solution. IA administration was performed by clinical investigators experienced with the use of the IA injection route.

The efficacy variable of primary interest was the change in pain intensity evaluated as change of WOMAC VA 3.1 A (total pain) subscore (A1-5, VAS 0-500 mm) from baseline over 2 weeks post treatment. Secondary measures included WOMAC Index, WOMAC stiffness (B) and functional impairment (C) subscores, pain at rest, pain after 15 meters walk (100 mm VAS) and patient global assessment (PGA) scores.

Safety was assessed by monitoring of lab tests, vital signs, ECG, physical examinations including the target knee, adverse events and concomitant medications.

Results:

All randomized patients (Intention-to-Treat-ITT, n=431) were allocated to the study treatment; with FAS 1mg (n=108), FAS 2.5 mg (n=108), FAS 5mg (n=107) and Placebo (n=108), with balanced demographic and baseline characteristics across treatment arms. Single IA injections of fasitibant did not significantly discriminate for WOMAC A pain over Placebo, with all treatments showing a decrease at week 1 and at week 2 post administration (Table 1). The time to first use of rescue medication (secondary endpoint) discriminated significant from placebo in the fasitibant 5 mg dose group (Kaplan-Meyer analysis; p< 0.0154). Fasitibant was well tolerated. There were no related SAEs. The majority of TESSs were mild or moderate. Severe TESSs occurred only in 12 patients (2.8%). Only 29 TESSs were considered related, most of them in placebo group (n=13). Lab tests, ECGs and vital signs were in general unremarkable and similar between treatments.

Conclusion:

The primary efficacy analysis has not shown any statistical significant evidence of superiority of fasitibant at any dose overPlacebo on pain reduction from baseline over 2 weeks after randomisation; however fasitibant 5 mg treated patients used statistically significant less rescue medication, which might be considered as an indirect evidence of its efficacy. The very high placebo response as well as the long duration of OA-symptoms (8.5±7.06 years) in all treatment groups may have contributed to the lack of efficacy as reported for other RCT in patients with symptomatic knee OA. Fasitibant was in general safe and local tolerability at the target knee was good.

Table 1: Change versus baseline for WOMAC pain over two weeks (ITT Population)

WOMAC A

(0-500 mm VAS)

Placebo

 

 

(N=108)

Fasitibant

1 mg

 

(N=108)

Fasitibant

2.5 mg

 

(N=108)

Fasitibant

5 mg

 

(N=107)

Overall

 

 

(N=431)

Baseline

Mean/%

(SD)

275.5/100%

(39.81)

286.5/100 %

(40.04)

282.7/100%

(40.08)

278.3/100%

(38.11)

280.8/100%

(39.61)

1 week post treatment

Mean/%

(SD)

-93.7/-34.5%

(94.15)

-91.8/-32.7%

(101.85)

-110.0/-39.5%

(99.48)

-109.8/-39.7%

(94.65)

-101.3/-36.6%

(97.63)

2 weeks post treatment

Mean/%

(SD)

-117.2/-42.9%

(90.15)

-106.1/-37.5%

(101.88)

-131.5/-47.4%

(96.41)

-115.9/-42.2%

(104.61)

-117.7/-42.5%

(98.48)

Inferential analysis over two weeks: Fasitibant  1 mg vs. placebo p=0.5156, Fasitibant 2.5 mg vs. Placebo p=0.2505, Fasitibant 5 mg vs. Placebo p=0.5739


Disclosure: C. G. Werner, Menarini Ricerche S.p.A., 3; K. Pavelka, None; A. Nizzardo, Menarini Ricerche S.p.A., 3; C. Rossi, Menarini Ricerche S.p.A, 3; S. Scartoni, Menarini Ricerche S.p.A., 3; M. P. Contini, Menarini Ricerche S.p.A., 3; S. di Molfetta, Menarini Ricerche S.p.A., 3; M. Bertolotti, Menarini Ricerche S.p.A., 3; A. Capriati, Menarini Ricerche S.p.A., 3; C. A. Maggi, Menarini Ricerche S.p.A., 3.

To cite this abstract in AMA style:

Werner CG, Pavelka K, Nizzardo A, Rossi C, Scartoni S, Contini MP, di Molfetta S, Bertolotti M, Capriati A, Maggi CA. A Double-Blind, Randomized, Controlled, Four Parallel Arm, Dose-Finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Single Intra-Articular (IA) Injections of Fasitibant in Patients with Symptomatic OA of the Knee [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/a-double-blind-randomized-controlled-four-parallel-arm-dose-finding-study-to-evaluate-the-efficacy-safety-tolerability-and-pharmacokinetics-of-single-intra-articular-ia-injections-of-fas/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-double-blind-randomized-controlled-four-parallel-arm-dose-finding-study-to-evaluate-the-efficacy-safety-tolerability-and-pharmacokinetics-of-single-intra-articular-ia-injections-of-fas/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology